Abstract
BackgroundPneumonia is a relevant clinical and public health issue worldwide frequently associated with infections caused by Multi-Drug Resistant (MDR) pathogens. Ceftaroline fosamil is a promising new antibiotics with broad-spectrum bacterial activity. The aim of this systematic review and meta-analysis is to assess the efficacy and the effectiveness of ceftaroline fosamil in community-acquired (CAP), hospital-acquired (HAP), healthcare-associated (HCAP) and ventilator-associated (VAP) pneumonia.MethodsA systematic review and meta-analysis was carried out retrieving both experimental and observational studies.ResultsA total of 2364 records was found and 14 manuscripts were finally considered eligible. The pooled efficacy/effectiveness was 81.2% (I2: 1.2%) in all types of pneumonia. The pooled relative risk of clinical cure was 1.1 (I2: 0.0%). The success rate was higher than 70% for infections caused by S. pneumoniae and S. aureus, including MDR pathogens.ConclusionsCeftaroline fosamil showed a high efficacy/effectiveness in patients with any type of pneumonia with a good safety profile.
Highlights
Pneumonia is a relevant clinical and public health issue worldwide frequently associated with infections caused by Multi-Drug Resistant (MDR) pathogens
Mortality for community-acquired pneumonia (CAP) ranges from < 5% among outpatients up to 30% in those admitted in an intensive care unit [2]
Over the past two decades, antimicrobial resistance has become a tangible reality for patients with hospital-acquired (HAP), ventilator-associated (VAP) or healthcare-associated (HCAP) pneumonia and for those coming from the community [5]
Summary
Pneumonia is a relevant clinical and public health issue worldwide frequently associated with infections caused by Multi-Drug Resistant (MDR) pathogens. Over the past two decades, antimicrobial resistance has become a tangible reality for patients with hospital-acquired (HAP), ventilator-associated (VAP) or healthcare-associated (HCAP) pneumonia and for those coming from the community [5]. It has been recognized as a clinical and public health threat, which should be immediately addressed in order to avoid a dramatic back to a pre-antibiotic era. The research and development activities of the pharmaceutical companies in the bacterial field have significantly decreased since the 1980s’ for several reasons, including an increased prevalence of chronic diseases, the complex design of the clinical trials requested
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
